Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.0K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.2K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.2K
Cancer Prevention02:59

Cancer Prevention

7.0K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.0K
Cancer02:18

Cancer

51.1K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.1K
What is Cancer?02:12

What is Cancer?

12.3K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
12.3K
Cancer Survival Analysis01:21

Cancer Survival Analysis

482
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
482

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1).

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Recalibrating Dual Checkpoint Blockade? Lessons from Volrustomig.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Aging dictates tumor-specific genomic alterations across cancer types.

npj aging·2026
Same author

Neighborhood Socioeconomics and Lung Cancer Recurrence and Progression.

Clinical lung cancer·2026
Same author

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Oct 28, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.6K

Lung cancer.

Alesha A Thai1, Benjamin J Solomon1, Lecia V Sequist2

  • 1Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia.

Lancet (London, England)
|July 17, 2021
PubMed
Summary
This summary is machine-generated.

Lung cancer remains a leading cause of cancer deaths globally. Recent advancements in targeted therapies and immune checkpoint inhibitors have significantly improved treatment outcomes for both non-small-cell and small-cell lung cancer.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.7K
Lung Tumor Cell Recruitment Assay
04:28

Lung Tumor Cell Recruitment Assay

Published on: February 26, 2019

5.6K

Related Experiment Videos

Last Updated: Oct 28, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.6K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.7K
Lung Tumor Cell Recruitment Assay
04:28

Lung Tumor Cell Recruitment Assay

Published on: February 26, 2019

5.6K

Area of Science:

  • Oncology
  • Pulmonology
  • Cancer Research

Background:

  • Lung cancer is a major global health concern, causing millions of deaths annually.
  • Significant progress has been made in understanding lung cancer biology and treatment over the last 20 years.

Purpose of the Study:

  • To provide a comprehensive overview of recent advancements in lung cancer care.
  • To highlight progress in screening, diagnosis, and treatment strategies for lung cancer.

Main Methods:

  • Review of current literature and clinical data on lung cancer.
  • Focus on targeted therapies and immune checkpoint inhibitors.

Main Results:

  • Advances in predictive biomarkers have refined treatment selection.
  • Targeted therapies and immune checkpoint inhibitors have transformed patient outcomes.

Conclusions:

  • Continued research and application of novel therapies are crucial for improving lung cancer survival.
  • Personalized medicine approaches are key to managing non-small-cell and small-cell lung cancer effectively.